New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

Aromatase inhibitor (AI) treatment is first-line systemic treatment for the majority of postmenopausal breast cancer patients with estrogen receptor (ER)-positive primary tumor. Although many patients benefit from treatment, some will develop resistance, and models mimicking acquired resistance will...

Descripción completa

Detalles Bibliográficos
Autores principales: HOLE, STINE, PEDERSEN, ASTRID M., HANSEN, SUSANNE K., LUNDQVIST, JOHAN, YDE, CHRISTINA W., LYKKESFELDT, ANNE E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356498/
https://www.ncbi.nlm.nih.gov/pubmed/25625755
http://dx.doi.org/10.3892/ijo.2015.2850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356498/
https://www.ncbi.nlm.nih.gov/pubmed/25625755
http://dx.doi.org/10.3892/ijo.2015.2850

Ejemplares similares